Burak Cem – VP & General Manager, Novo Nordisk Turkey
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Address: Nispetiye Caddesi, Akmerkez, E3 Blok, Kat:7 Etiler, Istanbul, Turkey 34335, Turkey
Tel: +90 212 3854040
Web: http://www.novoturk.com/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in 190 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Providing solutions mainly in Diabetes and Haemophilia
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Would you like to provide our international readers with a brief introduction into Novo Nordisk’s Turkish affiliate? As you may know, Novo Nordisk has a rich history of over 85…
Murat Barlas, the longest serving board member for the Turkish Pharmaceutical Manufacturers Association, discusses the need for a new perspective in government-industry relations in the Turkish pharmaceutical industry, and the…
The Turkish minister of labour and social security comments on the country’s deep commitment to providing for the health of citizens while maintaining sustainability and continuous improvement of services. How…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Turkey is a key market in the region for Servier, says general manager Philippe Méa, largely due to the country’s relatively strong and stable vision for the healthcare industry. The…
Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness…
Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently…
Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years. How did Medipol come into existence,…
Professor Burak Erman, the leader of the Drug Research Center at Koç University, and his colleague Hakan Orer, discuss the early activities of the center as a catalyst for collaboration…
Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement.…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim…
Turkey’s Minister of Health discusses the major achievements of his party in the area of healthcare since 2003, and the key priorities for the country’s healthcare system moving forward. During…
See our Cookie Privacy Policy Here